2 Biotech Stocks Worth Buying Before Their Potential Buyouts

The article highlights Legend Biotech and BioNTech as potential takeover targets amid renewed pharma M&A activity, including $65 billion in first-quarter sector deal value and recent deals worth $11.75 billion and $10.9 billion. Legend’s Carvykti generated $597 million in Q1 sales, up 62% year over year, while BioNTech holds 16.8 billion euros in cash and has more than 25 phase 2/3 trials plus six late-stage readouts expected this year. The piece is bullish on both names as strategic acquisition candidates, though it is largely speculative rather than event-driven.

Analysis

The market is likely underpricing how much strategic optionality has shifted from “science risk” to “execution and governance risk.” For both names, the key second-order effect is that a credible commercialization base plus a visible partnership ecosystem makes acquisition economics easier to underwrite than in a typical pre-revenue biotech, which should compress the usual discount to intrinsic value as M&A sentiment remains hot. That said, the bid premium is not the only path to upside: even absent a deal, a rerating can come from the market treating these as platform assets rather than binary trial stories.

LEGN has the cleaner near-term setup because the asset is already monetizing and the manufacturing footprint becomes strategic in an industry where capacity, QA, and turnaround time are increasingly the bottleneck. The hidden risk is that this same operational strength can reduce urgency for a buyer: if J&J can keep harvesting economics through the partnership without paying control premiums, the takeout clock may be longer than momentum traders expect. BioNTech is more interesting as a governance/cash-engineered call option; the cash balance effectively lowers downside, but it also means buyers can wait for data readouts rather than rush into an expensive acquisition.

The contrarian view is that consensus is overestimating “any deal is inevitable” while underestimating timing dispersion. For LEGN, the right catalyst is not rumor but evidence that Carvykti can sustain durable peak-sales growth without manufacturing degradation; for BNTX, the critical inflection is whether multiple late-stage readouts de-risk a portfolio wide enough to justify a strategic bid. The next 1-3 quarters matter more than the next 1-3 days: if data disappoints, these names can quickly revert to cash-burn multiple compression despite M&A enthusiasm.

The cleaner relative-value expression is not outright long-only but long the platform with tangible manufacturing leverage and short the higher-expectation, cash-rich name if the market keeps paying for optionality without a clear catalyst. In this tape, premiums will accrue to assets that shorten time-to-revenue and reduce integration risk for acquirers.

Key Decisions for Investors

• Long LEGN / short XBI for 1-3 months: express the view that scarce commercial cell-therapy assets with manufacturing infrastructure will outperform the broader biotech basket if M&A bid premium persists; target 10-15% relative outperformance, stop if biotech risk appetite rolls over.
• Buy LEGN common on pullbacks rather than chasing headlines; use a 2-4 week entry window and size for a 15-20% upside capture if takeover speculation re-accelerates, with 8-10% downside if deal chatter fades.
• Hold or initiate a smaller BNTX long only into major readouts over the next 1-2 quarters; the cash balance supports downside, but position sizing should reflect that a strategic bid is more timing-sensitive than the market implies.
• For event-driven accounts, buy LEGN call spreads 3-6 months out to monetize M&A optionality while capping premium bleed; prefer structures that pay if the stock re-rates on one data point or one strategic rumor.
• Avoid pairing long LEGN and long BNTX as if they are the same trade; LEGN is a commercialization/manufacturing story, while BNTX is a governance-and-pipeline sequencing story, and the catalysts are not synchronized.